SOCIODEMOGRAPHIC CHARACTERISTICS OF SARS-COV-2 SEROSURVEILLANCE

STUDIES WITH DIVERSE RECRUITMENT STRATEGIES, CANADA, 2020 TO 2023

- 3 Matthew J. Knight¹, Yuan Yu¹, Jiacheng Chen¹, Sheila F. O'Brien^{2,3}, David L. Buckeridge^{1,4},
- 4 Carmen Charlton^{5,6}, W. Alton Russell^{1,4}
- 1. Department of Epidemiology, Biostatistics and Occupational Health, School of Population and
- Global Health, McGill University, Montreal, Canada
- 2. Canadian Blood Services, Ottawa, Canada
- 3. School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada
- 4. COVID-19 Immunity Task Force, Montreal, Canada
- 5. Canadian Blood Services, Edmonton, Canada
- 6. Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
- **Corresponding author**: Matthew J. Knight (matthew.knight@mail.mcgill.ca), +1-613-854-9571
- Suite 1200, McGill College Avenue, Montreal, QC, Canada H3A 1G1
- **Keywords**: Representativeness; Surveillance; COVID-19
-
-
-
-
-
-

ABSTRACT

 Background. Serological testing was a key component of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) surveillance. Social distancing interventions, resource limitations, and the need for timely data led to serosurveillance studies using a range of recruitment strategies, which likely influenced study representativeness. Characterizing representativeness in surveillance is crucial to identify gaps in sampling coverage and to assess health inequities. **Methods**. We retrospectively analyzed three pre-existing longitudinal cohorts, two convenience samples using residual blood, and one de novo probabilistic survey conducted in Canada between April 2020 – November 2023. We calculated study specimen counts by age, sex, urbanicity, race/ethnicity, and neighborhood deprivation quintiles. We derived a 'representation ratio' as a simple metric to assess generalizability to a target population and various sociodemographic strata. **Results**. The six studies included 1,321,675 specimens. When stratifying by age group and sex, 65% of racialized minority subgroups were moderately underrepresented (representation ratio < 0.75). Representation was generally higher for older Canadians, urban neighborhoods, and neighborhoods with low material deprivation. Rural representation was highest in a study that used outpatient laboratory blood specimens. Racialized minority representation was highest in a de novo probabilistic survey cohort. **Conclusion**. While no study had adequate representation of all subgroups, less traditional recruitment strategies were more representative of some population dimensions. Understanding demographic representativeness and barriers to recruitment are important considerations when designing population health surveillance studies.

INTRODUCTION

 Serological surveillance is a critical input to infectious disease control, including pandemic preparedness and response. In 2020, Canada launched the largest serological surveillance program in its history to monitor population immunity to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), informing COVID-19 epidemiology and antibody dynamics. Between April 2020 and February 2021, many studies began testing blood specimens for SARS- CoV-2 antibodies [1–6]. Challenged by social distancing measures, studies used diverse strategies to recruit participants or obtain blood samples. Recruitment strategy influences study population's characteristics and the extent to which participants represent the general population [7]. Serosurveillance studies can be broadly categorized as convenience samples, de novo probabilistic surveys, or pre-existing longitudinal cohorts. For SARS-CoV-2 serosurveillance, many countries used convenience samples of residual blood specimens due to low operational costs and ease of continued sample collection over time [1,2,8,9]. Convenience samples may introduce selection bias if certain subpopulations are excluded or poorly represented [1,8]. Probabilistic serosurveys, also deployed in many regions to monitor SARS-CoV-2, can mitigate selection biases by using stratified, weight-based approaches to recruitment. De novo designs allow tailoring recruitment to study objectives [4,5,10–12]. However, probabilistic designs are time- and resource-intensive and are sometimes limited by low response rates [6,13]. Sampling within pre-existing longitudinal cohorts can improve efficiency by leveraging an established sampling frame and study infrastructure. But this precludes tailoring the sampling frame to the current research question, and generalizability may be limited by inclusion criteria or attrition.

METHODS

Data

 We assessed representativeness by analyzing demographic data from six Canadian study populations (Table 1). Here, we define a study to be representative if the sociodemographic composition of the study population matched the census-based target population; we make no assumptions of the sampling mechanism or inferential validity. This similarity suggests the interpretation of an effect measure may be generalizable to the target population, but does not assume the effect estimate, within an uncertainty interval, will be identical between the study and target populations [14]. The six studies included one de novo cross-sectional probabilistic sample (the Canadian COVID-19 Antibody and Health Survey 1 [CCAHS-1]), one open longitudinal 83 cohort recruited from a marketing research panel (Action to Beat Coronavirus study [Ab-C]), two pre-existing closed longitudinal cohorts (the Canadian Longitudinal Study on Aging COVID-19 Antibody Study [CLSA], the Canadian Partnership for Tomorrow's Health COVID- 19 Antibody Study [CanPath]), and two serial cross-sectional convenience samples that used residual blood from blood donations (Canadian Blood Services [CBS]) and specimens collected 88 for outpatient laboratory testing (Alberta Precision Laboratories [APL]). The included studies

114 **Table 1**: Summary of SARS-CoV-2 serological study designs included in the study.

115 Notes: ^aFour specimens were collected from Yukon territory and were excluded from all analyses. ^bComposed of

116 comprehensive sub-cohort and tracking sub-cohort that recruited participants from seven and 10 provinces,
117 respectively. Composed of six distinct regional cohorts. AB: Alberta; BC: British Columbia; MB: Manitob

respectively. Composed of six distinct regional cohorts. AB: Alberta; BC: British Columbia; MB: Manitoba; NB: 118 New Brunswick; NL: Newfoundland and Labrador; NT: Northwest Territories; NS: Nova Scotia; NU: Nunavut;

118 New Brunswick; NL: Newfoundland and Labrador; NT: Northwest Territories; NS: Nova Scotia; NU: Nunavut; 0N: Ontario; PE: Prince Edward Island; QC: Quebec; SK: Saskatchewan; YT: Yukon.

119 ON: Ontario; PE: Prince Edward Island; QC: Quebec; SK: Saskatchewan; YT: Yukon.

120

121

 From each dataset, we extracted participants' age, sex, postal code, date of specimen collection, and self-reported race/ethnicity. We used the postal code to classify participants' residence as urban or rural and to assign participants' neighborhood to a quintile of the Pampalon material and social deprivation indices [18]. Material deprivation is a composite measure of education, employment, and income reflecting access to essential material resources. Social deprivation is a composite measure of living alone, single-parent families, and people who are either separated, divorced, and/or widowed, reflecting the fragility of social networks. Both measures are derived 130 from the 2016 Canadian census [19]. We used the date of specimen collection as the sample date when available (CBS, APL); otherwise, we used the date of questionnaire completion (CanPath, CCAHS-1, CLSA) or specimen receipt (Ab-C).

 Race/ethnicity information was unavailable for the APL study. Deprivation indices were available for the CBS, APL, CCAHS-1, and CLSA studies. Specimen counts for the CCAHS-1 study were rounded to base 2000 in accordance with data usage guidelines. Age was calculated as the age at specimen collection (Ab-C, APL, CBS) or questionnaire completion (CanPath, CLSA, CCAHS-1) and categorized as 0-17 years, 18-26 years, 27-36 years, 37-46 years, 47-56 years, or 57 years and older. For Ab-C specimens collected between December 2020 – April 2021 and July 2021 – September 2021, we used the 2019 baseline age since the age at current collection could not be calculated. We categorized sex as male or female and excluded 142 participants who provided alternative responses ($n = 138$ [Ab-C]) from analyses involving participant sex. Because race/ethnicity data collection varied between studies and differed from census categorization, we re-classified participants as 'white' and 'racialized minority' and did not analyze specific racialized minority groups (Supplementary Tables S1-S2). For studies

 allowing multiple encounters with participants, we imputed missing variables when available for another encounter (CBS, Ab-C, CLSA). We classified participants who identified as both white and a racialized minority as a racialized minority, and we considered Indigenous identities as a racialized minority but conducted sensitivity analyses with different classifications. Because only CCAHS-1 collected specimens from the capital cities of the Canadian territories, we restricted our primary analysis to specimens collected from Canadian provinces but assessed territorial representativeness for CCAHS-1 separately. We excluded participants who did not meet the inclusion criteria of their respective study and who were missing age, province/territory of residence, or serology test result data. For the CBS study, we did not assess the representativeness of the 0-17-year-old age group because there were no donors younger than 17. We calculated specimen counts using complete cases within each set of demographic strata (e.g., participants missing race/ethnicity were excluded when stratifying by age, sex, and race/ethnicity but not when stratifying by age, sex, and urbanicity). 

Representation ratio analysis

 To assess the representativeness of subgroups defined by one or more sociodemographic variable, we derived a *representation ratio* by dividing the proportion of study specimens in a sociodemographic subgroup by the proportion of participants in the subgroup from a target population. A representation ratio less than one indicates the group is underrepresented relative to the target population, and a ratio greater than one indicates overrepresentation. We defined the target subgroup distribution using weighted 2016 Canadian census counts [19], restricting by age and province/territory to match studies' inclusion criteria (Table 1) and rounded to the nearest multiple of zero or five. We calculated representation ratios on unweighted study populations to

Representation ratio analysis

 Studies had reasonable representation across sexes (representation ratio 0.7-1.3; Figure 1) and, when available, by social deprivation (Supplementary Figure S5). In all studies, racialized minority subgroups were underrepresented (representation ratio < 1) for some age and sex strata (Figure 2). Racialized minority representation, while still low, was often better in older age groups (Ab-C, CanPath, and CLSA), but was better for younger age groups among women for CBS. Urban regions produced larger representation ratios by age and sex strata than rural regions

241 **Figure 1: SARS-CoV-2 serological study representativeness by sex, urbanicity, and**

242 **racial/ethnic identity.** Representativeness was calculated by dividing the proportion of study

243 specimens collected from a subgroup by the proportion of general population in the subgroup.

244 Total population counts were estimated using the 2016 Canadian census [19]. Bolded

245 representation ratios indicate greater than 95% of subgroup bootstrap replicates produced

246 representation ratios below 0.75. Bootstrapping was not performed for studies with weighted

247 representation ratios (CCAHS-1).

248

240

249

250

253 **Figure 2: SARS-CoV-2 serological study representativeness by age group, sex, urbanicity,** 254 **racial/ethnic identity, and material deprivation quintile.** Representativeness was calculated 255 by dividing the proportion of study specimens collected from a subgroup by the proportion of 256 general population in the subgroup. Total population counts were estimated using the 2016 257 Canadian census [19]. Material deprivation scores were not available for Ab-C and CanPath 258 studies. Bolded representation ratios indicate greater than 95% of subgroup bootstrap replicates 259 produced representation ratios below 0.75. Bootstrapping was not performed for studies with 260 weighted counts (CCAHS-1).

Sample count analysis

 The convenience samples with large overall sample size produced substantially more cells with counts greater than 25 across 4 levels of stratification compared to all other study designs in the primary analysis (Table 2) and sensitivity analysis (Supplementary Table S4). Pre-existing

307 **Table 2**: Percentage of SARS-CoV-2 serology study demographic subgroups with greater than

308 25 collected specimens.

309 *Notes:* Date of sample collection was binned into 2-month intervals for each level of stratification. All specimen counts were unweighted.

specimen counts were unweighted.

311

312

313

314

315

DISCUSSION

 In this study, we developed a simple method for characterizing study population representativeness and applied it to describe the variability in sociodemographic representativeness across six SARS-CoV-2 serosurveillance studies with diverse recruitment strategies. No study was adequately representative of all sociodemographic subgroups. Representation ratios are a flexible diagnostic measure for characterizing study populations. Ratios can consider any combination of characteristics for which reliable estimates of their distribution in a target population are available. Ratios can be used to compare study populations, even when target populations differ, and can be estimated before and after application of sample weights. Notably, representation ratios do not provide insights into the relationship between participant characteristics and a study's estimand, and do not address unmeasured confounding within subgroups.

 Probabilistic surveys have traditionally been considered the 'gold standard' for obtaining representative samples [7]. Use of administrative datasets to construct sampling frames often provides superior population coverage compared to non-probability samples that rely on participant self-selection. The statistical framework also permits estimation of sampling errors and characteristics associated with non-response [22]. While resource constraints may limit the ability of probabilistic designs to perform repeated specimen collection, non-probability sampling within continuous streams of residual blood specimens, such as blood donors, may be more feasible for modelling longitudinal trends, which can also incorporate complex geographic structures [23]. The generalizability of probabilistic designs may also be limited if differences

 between respondents and non-respondents are non-random [7]. Bias may be introduced via a 'healthy volunteer' effect whereby cohort participants are healthier than the general population [24], similar to the 'healthy donor' bias documented in blood donor research cohorts [25]. Where available, response rates of the included studies were fairly low (23% [CCAHS-1], 25% [Ab-C] [6,12]; these response rates exclude individuals who completed a questionnaire but did not provide a blood sample). This suggests non-response bias could partially explain some of the observed differences in representativeness between study designs. The above response rates are consistent with other probabilistic serosurveys [11], although response rates as high as 69% have been reported [10].

 Many large-scale SARS-CoV-2 studies relied on blood donor and healthcare patient populations for serology specimens [22,26]. Blood donors have been discounted as a population for public health surveillance, while the potential for expanded screening of residual outpatient laboratory samples remains unclear. However, we found the representativeness of these convenience populations compared favorably to other designs for some sociodemographic dimensions. For low- and middle-income countries with limited operational resources, leveraging residual blood samples may provide a cost-effective avenue to obtain representative data. Future studies should evaluate the potential of linkage to administrative datasets to better characterize representativeness and derive statistical weights for adjustment. Gaps in demographic representation may be overcome by synthesizing data from multiple surveillance streams, though differences in choice of assay, use of venous blood draws or dried blood samples, and the format or availability of variables can curtail the ability to synthesize data across studies [27,28].

 Racialized minorities were underrepresented across all studies. Language barriers and skepticism of research or medical institutions may contribute to poor representation of some minority groups [29,30]. While use of stratified random sampling or sampling weights may improve sample representativeness, they do not address the underlying individual and societal factors governing participation in health research. Direct engagement and collaboration with community members throughout the research cycle may mitigate recruitment barriers by facilitating trust, reducing misinformation, and ensuring study materials are accessible [30,31]. Racialized minorities may be better represented in healthcare cohorts like APL [32], though a lack of race- based data in Canadian administrative healthcare datasets may make this difficult to measure [33]. Notably, representation of racialized minorities improved as age increased in most studies requiring participant opt-in (Ab-C, CLSA, CanPath), but young minorities exhibited better representativeness compared to older subgroups in CBS. Lack of a standardized definition of participant race/ethnicity impeded comparison across studies and prevented assessment of representativeness by specific minority group.

 Several other dimensions of representativeness varied across studies. The Ab-C open cohort was substantially more representative of 18-46-year-olds across sex and urbanicity strata compared to the CanPath longitudinal closed cohort (Figure 2). CLSA and CanPath recruited participants aged 45-85 in 2010 and 35-74 in 2009, respectively, leading to older age distributions for their COVID-19 sub-studies [15,16]. Between convenience samples, individuals residing in highly materially deprived areas were underrepresented when using blood donations (representation ratio 0.4–0.6), but not when using outpatient labs (representation ratio 0.9-1.2). Donor eligibility criteria, along with the 'healthy donor effect' or other unmeasured socioeconomic factors, may

 homogenize the demographic composition of the sampled donor pool [25]. Rural regions were consistently underrepresented compared to urban counterparts in all studies, which may be due to urban-centric recruitment patterns or willingness to travel for specimen collection (Figures 1-2).

 The study had several limitations. First, our analysis considered representativeness by age, sex, race/ethnicity, urbanicity, and neighborhood deprivation. Many other sociodemographic dimensions are important considerations for representativeness in serosurveillance studies, particularly those related to health and disability. We hypothesize a 'healthy participant' sampling bias may have led to underrepresentation of individuals with poor health and/or disability in all study populations except outpatient laboratories [24,25]. Prior analyses of the pre-existing longitudinal cohorts included in our study indicated participants are more educated and/or have higher income than the general population [12,15,16], as are blood donors in the United States [34]. Second, the measurement of race/ethnicity differed between studies. Race/ethnicity options for CBS included four mutually exclusive categories, while the Ab-C, CCAHS-1, CanPath, CLSA, and census datasets permitted selection of multiple racial/ethnic identities. This necessitated dichotomizing the race/ethnicity variable as white or racialized minority and may have biased the CBS representation estimate if individuals who identified as mixed race/ethnicity selected their race/ethnicity as white during donation. Additionally, due to unavailable Indigenous identity data, we modified our representation assessment for the CLSA and CanPath studies by omitting Indigenous-identifying individuals from the census dataset. Our sensitivity analysis suggests this did not substantially impact our findings (Supplementary Figure S16). Third, we restricted our analysis to SARS-CoV-2 serostudies conducted within a single country and used an acceptability level of underrepresentation that is context-specific and open

the need to adopt a standardized approach to the measurement of self-identified race/ethnicity in

- Canada.
-

ABBREVIATIONS

DECLARATIONS

Ethics approval and consent to participate

- All studies analyzed were approved by a Research Ethics Board or Institutional Review Board of
- a Canadian institution as reported previously. This secondary analysis of six studies was
- approved by the McGill University Faculty of Medicine and Health Sciences Research Ethics
- Board (study number 22-03-077).

Consent for participation

Not applicable.

- **Availability of data and materials**
- The authors are not authorized to share individual-level data from any study. Processes are
- available for researchers to request access to datasets for studies that have undergone
- institutional ethical approval. Data from Canadian Blood Services and Alberta Precision

- Laboratories may be made available upon request, subject to internal review, privacy legislation,
- data sharing agreements, and research ethics approval. The CCAHS-1 study by Statistics Canada
- can be analyzed for approved projects at Research Data Centres located across Canada
- (https://www.statcan.gc.ca/en/microdata/data-centres/access). Data are available from the
- Canadian Longitudinal Study on Aging (www.clsa-elcv.ca) for researchers who meet the criteria
- for access to de-identified CLSA data. Access to the Ab-C study data can be requested through
- the COVID-19 Immunity Task Force Databank (https://portal.citf.mcgill.ca/). Access to the
- CanPath data can be requested through the CanPath data portal (https://portal.canpath.ca/).
- Analytical code will be available in a public repository upon publication.

Competing interests

- The authors declare that they have no competing interests.
- **Funding**
- WAR was supported by funding from Canadian Blood Services and the COVID-19 Immunity Task Force.

Authors' contributions

- MJK and WAR designed the study with input from DLB, SFO, and CC. MJK, YY, and JC
- contributed to data analysis. MJK and WAR drafted the initial manuscript. All
- authors revised the manuscript and approved the final version.

Acknowledgements

- This research was made possible using data collected by Canadian Blood Services' SARS-CoV-
- 2 Seroprevalence Study; the Canadian Partnership for Tomorrow's Health (CanPath formerly
- CPTP) COVID-19 Antibody study and its regional cohorts the BC Generations Project, Alberta's
- Tomorrow Project, the Ontario Health Study, CARTaGENE, Manitoba Tomorrow Project and

REFERENCES

- CoV-2 Seroprevalence by Social Determinants of Health. Microbiology Spectrum.
- 2023;11(1):e03356-22. 10.1128/spectrum.03356-22
- 2. Charlton CL, Nguyen LT, Bailey A, et al. Pre-Vaccine Positivity of SARS-CoV-2
- Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
- Microbiology Spectrum. 2021;9(1):e00291-21. 10.1128/Spectrum.00291-21
- 3. Jha, Prabhat. Action to beat Coronavirus study: Dataset contributed to the CITF
- Databank. Version DRAFT. Borealis. https://doi.org/doi:10.5683/SP3/LA2IKO
- 4. Canadian Longitudinal Study on Aging. Data Support Document SARS-CoV-2 Antibodies. 2024.
- 5. Canadian Partnership for Tomorrow's Health. COVID-19 initiatives. CanPath Canadian
- Partnership for Tomorrow's Health. Available from: https://canpath.ca/covid-19-initiatives/.
- 6. Statistics Canada. Canadian COVID-19 Antibody and Health Survey (CCAHS). 2020.
- Available from:
- https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&Id=1287991
- 7. Cornesse C, Bosnjak M. Is there an association between survey characteristics and
- representativeness? A meta-analysis. Survey Research Methods. 2018;12(1):1-13.
- 10.18148/srm/2018.v12i1.7205
- 8. Offergeld R, Preußel K, Zeiler T, et al. Monitoring the SARS-CoV-2 Pandemic:
- Prevalence of Antibodies in a Large, Repetitive Cross-Sectional Study of Blood Donors in

- 10.3390/pathogens12040551
- 9. Bogogiannidou Z, Vontas A, Dadouli K, et al. Repeated leftover serosurvey of SARS-
- CoV-2 IgG antibodies, Greece, March and April 2020. Eurosurveillance.
- 2020;25(31):2001369. 10.2807/1560-7917.ES.2020.25.31.2001369
- 10. Pérez-Gómez B, Pastor-Barriuso R, Fernández-de-Larrea N, et al. SARS-CoV-2
- Infection During the First and Second Pandemic Waves in Spain: The ENE–COVID Study.
- Am J Public Health. 2023;113(5):533-544. 10.2105/AJPH.2023.307233
- 11. Ward H, Atchison C, Whitaker M, et al. Design and Implementation of a National
- Program to Monitor the Prevalence of SARS-CoV-2 IgG Antibodies in England Using Self-
- Testing: The REACT-2 Study. Am J Public Health. 2023;113(11):1201-1209.
- 10.2105/AJPH.2023.307381
- 12. Tang X, Sharma A, Pasic M, et al. Assessment of SARS-CoV-2 Seropositivity During
- the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults. JAMA

Network Open. 2022;5(2):e2146798. 10.1001/jamanetworkopen.2021.46798

- 13. Patel EU, Bloch EM, Tobian AAR. Severe Acute Respiratory Syndrome Coronavirus 2
- Serosurveillance in Blood Donor Populations. The Journal of Infectious Diseases.
- 2022;225(1):1-4. 10.1093/infdis/jiab517
- 14. Rudolph JE, Zhong Y, Duggal P, et al. Defining representativeness of study samples in
- medical and population health research. BMJ Med. 2023;2(1):e000399. 10.1136/bmjmed-
- 2022-000399

- on Aging (CLSA). International Journal of Epidemiology. 2019;48(6):1752-1753j.
- 10.1093/ije/dyz173
- 16. Dummer TJB, Awadalla P, Boileau C, et al. The Canadian Partnership for Tomorrow
- Project: A pan-Canadian platform for research on chronic disease prevention. CMAJ.
- 2018;190(23):E710-E717. 10.1503/cmaj.170292
- 17. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of
- Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting
- observational studies. Epidemiology. 2007;18(6):800-804.
- 18. Pampalon R, Hamel D, Gamache P, et al. An area-based material and social deprivation
- index for public health in Québec and Canada. Can J Public Health. 2012;103(8 Suppl
- 2):S17-22. 10.1007/BF03403824
- 19. Statistics Canada. Census Profile, 2016 Census. 2017. Available from:
- https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E
- 20. Downes M, Carlin JB. Multilevel regression and poststratification as a modeling
- approach for estimating population quantities in large population health studies: A simulation
- study. Biometrical Journal. 2020;62(2):479-491. 10.1002/bimj.201900023
- 21. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
- Austria: R Foundation for Statistical Computing; 2023. https://www.R-project.org/.
- 22. Lindan CP, Desai M, Boothroyd D, et al. Design of a population-based longitudinal
- cohort study of SARS-CoV-2 incidence and prevalence among adults in the San Francisco
- Bay Area. Annals of Epidemiology. 2022;67:81-100. 10.1016/j.annepidem.2021.11.001

- seropositivity among Canadian blood donors. International Journal of Epidemiology.
- 2024;53(3):dyae078. 10.1093/ije/dyae078
- 24. Froom P, Melamed S, Kristal-Boneh E, et al. Healthy Volunteer Effect in Industrial
- Workers. Journal of Clinical Epidemiology. 1999;52(8):731-735. 10.1016/S0895-
- 4356(99)00070-0
- 25. Atsma F, Veldhuizen I, Verbeek A, et al. Healthy donor effect: Its magnitude in health
- research among blood donors. Transfusion. 2011;51(8):1820-1828. doi:10.1111/j.1537-
- 2995.2010.03055.x
- 26. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large
- nationwide sample of patients on dialysis in the USA: A cross-sectional study. *The Lancet*.
- 2020;396(10259):1335-1344. doi:10.1016/S0140-6736(20)32009-2
- 27. Mulchandani R, Brown B, Brooks T, et al. Use of dried blood spot samples for SARS-
- CoV-2 antibody detection using the Roche Elecsys ® high throughput immunoassay. Journal
- of Clinical Virology. 2021;136:104739. 10.1016/j.jcv.2021.104739
- 28. Patel EU, Bloch EM, Clarke W, et al. Comparative Performance of Five Commercially
- Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals
- with High Neutralizing Titers. Journal of Clinical Microbiology.
- 2021;59(2):10.1128/jcm.02257-20. 10.1128/jcm.02257-20
- 29. Etti M, Fofie H, Razai M, et al. Ethnic minority and migrant underrepresentation in
- Covid-19 research: Causes and solutions. eClinicalMedicine. 2021;36.
- 10.1016/j.eclinm.2021.100903

- strategies for improving health and medical research with socially disadvantaged groups.
- BMC Medical Research Methodology. 2014;14(1):42. 10.1186/1471-2288-14-42
- 31. Ekezie W, Czyznikowska BM, Rohit S, et al. The views of ethnic minority and
- vulnerable communities towards participation in COVID-19 vaccine trials. Journal of Public
- Health. 2021;43(2):e258-e260. 10.1093/pubmed/fdaa196
- 32. Anand S, Montez-Rath M, Han J, et al. Prevalence of SARS-CoV-2 antibodies in a large
- nationwide sample of patients on dialysis in the USA: A cross-sectional study. The Lancet.
- 2020;396(10259):1335-1344. 10.1016/S0140-6736(20)32009-2
- 33. Khan MM, Kobayashi K, Vang ZM, et al. Are visible minorities "invisible" in Canadian
- health data and research? A scoping review. International Journal of Migration, Health and

Social Care. 2017;13(1):126-143. 10.1108/IJMHSC-10-2015-0036

- 34. Patel EU, Bloch EM, Grabowski MK, et al. Sociodemographic and behavioral
- characteristics associated with blood donation in the United States: A population-based

study. Transfusion. 2019;59(9):2899-2907. 10.1111/trf.15415

- 35. Atkinson A, Albert A, McClymont E, et al. Canadian SARS-CoV-2 serological survey
- using antenatal serum samples: A retrospective seroprevalence study. Canadian Medical
- Association Open Access Journal. 2023;11(2):E305-E313. 10.9778/cmajo.20220045